Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can sunscreen do more than protect? study tests if it fades dark spots

NCT ID NCT07679945

Symptom relief Sponsor: Kenvue Brands LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests whether two types of facial sunscreen (untinted and tinted) can improve dark spots caused by melasma, sun spots, or post-inflammatory hyperpigmentation. Adult participants with mild to moderate dark spots apply the sunscreen at least twice daily for 56 days. Researchers measure changes in spot color and size using clinical evaluations, instruments, and photos, and also assess quality of life and participant satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
facial sunscreen (untinted and tinted)
What this could lead to
If effective, these sunscreens could offer a simple way to reduce dark spots and improve skin tone and quality of life.
What could go wrong
This is a small, open-label study without a placebo group, so results may be influenced by expectations. Effectiveness may vary by skin type and spot type.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 152 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Able to understand and follow study instructions 2. Fitzpatrick skin types I-VI 3. Presence of facial hyperpigmentation, such as: * Mild to moderate melasma, or * Visible dark spots (e.g., solar lentigines or post-inflammatory hyperpigmentation) 4. Willing to comply with study procedures and product use 5. For subjects in applicable groups: willing to use assigned sunscreen product Exclusion Criteria: 1. Known sensitivity or allergy to cosmetic or skincare products 2. Skin conditions or lesions in the study area that could interfere with evaluation (e.g., active dermatitis, infections, significant irritation, or extensive scarring) 3. Use of medications or products that may interfere with study evaluations 4. Recent cosmetic or dermatological procedures in the study area (e.g., chemical peels, laser treatments, invasive procedures) 5. Excessive sun exposure or use of tanning beds immediately prior to or during the study 6. Pregnancy or intention to become pregnant during the study 7. Participation in another clinical study within a recent period 8. Any condition or situation that, in the investigator's judgment, may interfere with study participation or evaluation of results

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melasma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hyperpigmentation lentigo Melanosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melasma Post-inflammatory hyperpigmentation Solar lentigo

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ALS Beauty & Personal Care Ltda

    RECRUITING

    Campinas, São Paulo, 13084-791, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.